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Abstract
Modern nuclear medicine frequently needs to be supported by 
software for calculations. A self-designed free-accessible online 
tool named “Calculator” is presented. It can be used from the 
web-site www.nuk.bieganski.org, option “Calculator”. The pro-
grams offer: calculations of quantity of a radionuclide after a time 
(equation of simple radioactive decay), quantity of the second and 
third nuclide in the decay chain (successive radioactive decay, 
computation with Bateman equations and their limits), converting 
of activity units as well as of activity of a radioactive substance 
into its mass and vice versa, and calculations related to radionu-
clide therapy (radionuclide uptake, effective half time and activity 
needed for therapy). Mathematical and historical backgrounds of 
the algorithms used are shortly discussed in this work. 
KEY words: simple decay, successive decay, Bateman 
equation, effective half time, delivered radiation dose, 
radionuclide therapy, computation
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Introduction
Nuclear medicine belongs to the most dynamically developing 
branches of medicine. Optimization of diagnostics and therapy with 
radionuclides by deploying recent achievements requires applica-
tion of software for performing calculations. A self-designed tool for 
such calculations, named “Calculator”, is presented. From known, 
commercially accessible tools designed for similar purposes, it dif-
fers that, among others, it is online- and free-accessible.
To access the “Calculator”, one has to go to the web-site of 
our Department (http://www.nuk.bieganski.org/) ﬁ rst. Unless your 
language is Polish, you have to choose English; the programs are 
accessible in these two languages. Then you can choose the option 
“Calculator” from the menu (green buttons, left side). The “Calcula-
tor” is accompanied by short manuals and examples of its use.
Simple radioactive decay
The activity of a nuclide 1, i.e., the rate of the radioactive decay 
(A1), is directly proportional to the amount (number of atoms) of the 
nuclide and its decay constant (l1):
The simple decay equation, i.e., the equation determining the 
number of atoms of the nuclide 1 after time t (Nt(1)), when the number 
of atoms at the beginning (t=0) is known (N0(1)), is:
A similar equation can be applied for calculation of the activity 
of the nuclide 1:
If the time t in the formulas is completed with a negative number, 
it will be possible to calculate the number of atoms or activity, re-
spectively, before the time, in which the number or activity is known. 
In this way, one can calculate, for example, the activity of iodine 
capsule before the time of calibration.
Because the half times of the nuclides (T1/2(1), time, after which 
the amount of the radioactive nuclide diminishes two-fold) are more 
useful than the decay constants, the equations can be written as:
and
Time, after which the nuclide would have decayed totally, if 
the decay process had have constant rate (if the activity had been 
the same as at the beginning throughout the entire time), is called 
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mean lifetime (t). The relation between the mean lifetime, decay 
constant and half time is: 
Successive radioactive decay
The term “Successive radioactive decay” describes a decay 
of a nuclide 1, which gives rise to nuclide 2, which is also radioac-
tive (and decays further to 3). The reaction equation is as follows:
nuclide 1 Æ nuclide 2 Æ nuclide 3 Æ ... .
The problem of quantity of the second and further daugh-
ter-nuclides in the radioactive chain was solved ﬁ rst by an English 
mathematician Harry Bateman (1882–1946) in 1910 [1]. The formu-
las describing the quantities are called Bateman-equations. Such 
a formula can be derived for any member of the chain given [2]. 
The complexity of the algebraic functions limits their use almost 
exclusively to computers.
The general equation for derivation of the formula for the number 
of atoms of the i-th nuclide is:
where
f(gÆg+1) — branching ratio of the g-th nuclide (i.e., the ratio of the 
g-th nuclide, which gives rise to the (g+1)-th nuclide; the remainder 
decays in a different way). It is also assumed that the amounts of 
all the nuclides in the chain (except for the nuclide 1) are zero at 
the beginning.
The general equation for the activity of the i-th nuclide is:
It should be emphasized, however, that all the nuclides in the 
chain must have different decay constants (i.e., different half times). 
Otherwise, the derived formula becomes incalculable because of 
zero in the denominator.
The derivation of the formula for the number of atoms of the 
second nuclide in the function of time is:
If the number of atoms of the second nuclide is higher than zero 
at the beginning, one must add to the above formula the number 
of atoms, which remains after decay of this amount of the second 
nuclide after the given time:
Analogously, the derivation of the formula for the activity of the 
second nuclide is:
For the situation, in what N0(2)=0, the time, after which the 
amount of the second nuclide reaches its maximum (tmax(2)), can 
be additionally calculated as the zero-point of the derivative of the 
above function:
For another situation (N0(2)>0), the appropriate derivative be-
comes a multistep exponential equation, which cannot be solved 
for time by use of analytical methods. Therefore, the time of maxi-
mum for such a case, as well as for a further nuclide in a chain, 
can be approached only by use of a successive approximation 
(iterative) method.
In theoretical cases, in which the decay constants of all the 
nuclides in the chain are the same, the general equation is:
The maximal amounts of the nuclides are reached after the 
time tmax(i):
(on condition that there is present only nuclide 1 at the beginning).
The derivation of the formulas for the number of atoms and 
activity of the second nuclide in such a case is:
and
respectively.
The derivation of the formulas for the third nuclide in all pos-
sible cases of the lambdas is more complicated. The formulas are 
given in Table 1.
Similar equations can be used for purposes other than radioac-
tive decay, as pharmacokinetic models [3]. Quantities (concentra-
tions, activities) of a radiopharmaceutical in an organ can also be 
approached by similar formulas, as described below.
Calculation of (radio)nuclide uptake
The determination of uptake of a radiopharmaceutical belongs to 
the most important and, sometimes, very challenging tasks of quan-
titative nuclear medicine. To get the value of the radionuclide uptake, 
one needs to know the quantity (practically: measure-value) of the 
radionuclide before its administration (the “100%-value”) and the 
quantity (measure) of the nuclide in the patient; obviously, both mea-
sures must be performed using the same technique. Especially the 
measure of the patient should be background-corrected; otherwise, 
the result will be overestimated. There are several techniques for 
estimation of the background, especially in planar imaging. One 
of them is to create the ﬁ rst region of interest (ROI) over the organ 
measured and the second in a close vicinity of the organ. To get the 
background-corrected value of the radionuclide uptake, one should 
subtract the (ROI-area-corrected) value of the background from the 
organ value and divide the result by the radionuclide value:
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The background can have diverse sources. For example, in 
planar imaging of the thyroid with iodine-131, it can result from circu-
lating iodide (especially during a few hours after iodine-application) 
or from circulating radioactive thyroid hormones (especially after 
a few days following the administration). The background-value, 
in our own experience, can exceed 10% of the organ-value after 
one effective half time.
By substitution of the value N0(1) in the simple decay equation 
with 1 and the t with the time interval between the radionuclide and 
the patient measures, one obtains the decay factor (the fraction 
of the nuclide what remains after its physical decay). After division 
of the radionuclide uptake by the decay factor, one obtains the 
“nuclide uptake” (how high would be the uptake of the nuclide, if 
it did not undergo radioactive decay), which corresponds to the 
pure pharmacological processes of the (radio)pharmaceutical in 
the organ.
Therapy with radionuclides
Radionuclide therapy dates back to the ravine of 1930’s and 
1940’s, when John Hundale Lawrence (1904–1991) (brother of Er-
nest Orlando Lawrence — 1901–1958 — the inventor of cyclotron) 
applied phosphorus-32 for treatment of leukemia [4]. The concept 
of radiotracer developed by György von Hevesy (1885–1966) 
paved the way for therapy with open radioactive sources [5]. The 
ﬁ rst radioiodine therapies of the thyroid were performed by the 
groups of Robley Dunglison Evans (1907–1995) [6–8] and Earl R. 
Miller (1907–1995) [9–12]. Primarily, a cyclotron-derived nuclide 
I-130 (half-time 12.36 h, mean beta-energy: 268 keV, gammas: 536, 
669 and 740 keV) was applied for this purpose. Later, cheaper and 
longer-living I-131 (half-time: 8.02 days, mean beta-energy: 181.9 
keV, gammas: mainly 364.5 keV) from reactor got the dominant 
position. Shortly thereafter, calcium and strontium nuclides (mainly 
Sr-89) were introduced for palliation of bone metastatic disease [13] 
(instead of highly myelotoxic P-32); the today popular radiolabeled 
(mainly with Sm-153) diphosphonates became known in 1980’s [14, 15]. 
At present time, there are many dynamically developing pos-
sibilities of therapy with radionuclides, including peptide receptor 
radionuclide therapy [16] and many others.
Parallel to the radionuclide therapies, methods of its optimi-
zation were developed. The goal was to make the therapy suc-
cessful by delivering of optimal radiation dose to the target organ 
(node, tumor, etc.) and to limit side effects caused by irradiation 
of normal tissues. Several strategies for calculation of the radia-
tion doses to the target tissues as well as to non-pathologically 
changed organs have been proposed. The most precise method 
of calculation of internal radiation dose is based on the amount 
of energy released by particles in a given mass of target tissue; 
it is assumed that the range of the particles is negligible small in 
comparison with the diameters of the target organ (node). It can 
be described by the following formula: 
where:
D — focal radiation dose (amount of energy delivered per mass unit)
Emean — mean energy of particle(s) per radioactive disintegration
m — target mass of the tissue (node)
A(t) — activity of the radionuclide in the target organ as a function 
of time. The integral of the function is equal to the total number of 
radioactive disintegrations (“cumulative activity”), what take place 
in the organ.
The activity of a radionuclide in an organ as a function of time 
can be approached by the Bateman equations, as mentioned 
above. Radioiodine therapy of thyroid is the most popular example 
of radionuclide therapy. If the iodine-131 is injected i.v. as bolus, 
the function of activity of the radioiodine over the thyroid can be 
approached by the Bateman equation for the second nuclide. If 
the iodine-131 is administered orally, the function is more complex 
and is similar to the equation for the third or a further nuclide. 
This function consists of an ascending branch (inﬂ ux of the iodide 
into the organ), a peak, and a descending branch (efﬂ ux — mainly 
hormone — and physical decay). In further considerations, it is as-
sumed that area under the ascending part of the curve is negligibly 
small in comparison with the area under the descending branch. 
The descending branch reﬂ ects the effective half time of the nu-
clide in the organ. In this way, one can derive a general formula 
for calculation of the necessary activity of iodine-131 (expressed 
in MBq) for treatment of thyroid diseases:
where:
D — focal radiation dose, which should be delivered to the tissue, 
expressed in greys
m — target mass, expressed in grams (since the density of the 
majority of tissues, including thyroid, is close to 1 g/ml, the target 
mass expressed in grams is almost equal to its volume expressed 
in ml)
U — maximal measured radioiodine uptake expressed in percent 
(the “peak”)
T(1/2)ef — effective half-time of the iodine-131 in the thyroid (node) 
expressed in days.
This formula was ﬁ rst proposed by Leonidas Marinelli (1906–
–1974) [17, 18]. For nuclides different from iodine-131, a correction 
for mean kinetic energies of the emitted particles must be made. 
Apart from this, the “Calculator” offers also a possibility to perform 
a next correction related to taking into consideration of the area 
under the ascending branch of the time-activity curve.
The focal radiation doses for several thyroid disorders are 
suggested in numerous guidelines [19, 20] (and listed in the 
programs). The target volume must be determined by imaging 
techniques, preferably by ultrasonography in case of thyroid. The 
maximal uptake can be directly measured or extrapolated from the 
time-uptake curve. The effective half time will be discussed below.
Effective half time
The descending branch of the curve of the nuclide activity 
over the organ is almost exponential; more precisely: the longer 
time interval after the peak, the more exponential is the curve. 
On a semi-logarithmic scale, the descending branch is almost 
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a straight line. This simpliﬁ es the calculation of the effective half 
time, if many measures have been made: it can be performed 
using the least square method. The “Calculator” makes possible 
to choose these points, which are placed on or near a straight 
line and not to choose these, what are far from it (they result most 
probably from erroneous measures). It is important to remember 
that results placed near or, especially, before the peak should not 
be taken into consideration for calculation of the effective half time; 
otherwise, the time would be overestimated.
There is a relation of the effective half time to the physical half 
time of the nuclide and to the biological half time (related to pure 
biochemical/pharmacological processes of a radiopharmaceuti-
cal in an organ): the reciprocal of the effective half-time T(1/2)ef 
equals to the sum of reciprocals of times: physical T(1/2)phys, and 
biological T(1/2)biol:
On the basis of this equation and the calculated effective 
half time, one can calculate the biological half time as well as the 
effective half time of another nuclide in the organ. However, one 
should remember that the method has its limitations. If a nuclide 
with shorter physical half time is used to determine the effective half 
time of a nuclide with much longer physical half time in an organ 
with relatively long biological half time of the pharmaceutical (for 
example: iodine-123 for determination of the effective half time of 
iodine-131 in thyroid), the procedure can result in an unacceptably 
high error.
The process of calculation of the effective half time may seem 
engaging and time-consuming because of multiple patient-mea-
sures. There exist publications on the half times of iodine-131 in 
the thyroid (nodes) in various pathological states [21]. However, 
the published half times are only mean values. For example, typical 
effective half time of iodine-131 in the thyroid of a Graves-Basedow 
patient slightly exceeds 4 days. In the author’s experience, however, 
there is known a female patient suffering from this disease with the 
measured effective half time of less than one day. If a “standard 
effective half time” had been used for the calculation of the admi-
nistered radioiodine activity, the method would have underestimated 
this activity more than four-fold.
It is noteworthy that the effective half time and maximal up-
take are not constant values of a subject. They can be inﬂ uenced 
by the course of the disease itself, but also by some drugs. For 
example, there are known data about lengthening of the effec-
tive half time of radioiodine in the thyroid with discontinuation of 
antithyroid therapy, administration of lithium salts as well as of 
non-radioactive iodine (after administration of the radioiodine) [22]. 
The uptake of radioiodine by thyroid cancer cells can also be 
enhanced with retinoids, glycerin tributyrate [23, 24] and glita-
zones [25]. In cases of therapy of the thyroid and its tumors, it 
is of course very important to keep in mind that pre-therapeutic 
contamination with (non-radioactive) iodine leads to diminished 
uptake of the radioiodine not only by competitive inhibition of the 
iodine transporter (similarly to a blockade of a receptor), but also 
through a speciﬁ c arrest of thyreocytes (phenomenon referred to 
as Wolff-Chaikoff-effect) [26]. An issue of changing the maximal 
uptake and/or effective half time by irradiation of the target tissue 
(even during the dosimetry measures) is controversial, but also 
exists [27–29]. These observations may lead to avoiding errors in 
radionuclide therapy and to its further optimization.
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